is now part of
DeepHealth is excited to announce the expansion of our AI-powered portfolio into routine imaging and acute care through the strategic acquisition of Gleamer.
Gleamer founded
Founded in Paris to bring clinically validated AI into radiology workflows.
BoneView launch
Began rolling out AI fracture detection.
ChestView launch
AI solution for chest X-ray interpretation.
BreastView, LungCT, BoneCT launch
AI support for lesion detection and triage in 2D/3D mammography.
Gleamer is now part of DeepHealth
Acquisition makes DeepHealth the global leader in AI-powered health informatics and services.
RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide
LOS ANGELES and PARIS — March 2, 2026 — RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a U.S. leader in outpatient diagnostic imaging services, announced today it has acquired Gleamer SAS (“Gleamer”), a leading radiology AI company based in Paris, France, to be integrated into DeepHealth, RadNet’s wholly owned subsidiary. The acquisition further expands DeepHealth’s AI-powered health informatics solutions and services, making it the largest provider of radiology clinical AI solutions worldwide2.
Read more
Empowering breakthroughs in care by unlocking the value of imaging
DeepHealth is a global leader in AI-powered health informatics for real-world settings, delivering the industry’s most comprehensive integrated portfolio of solutions and services. Our solutions address both clinical and operational challenges that arise in complex, high-volume care settings, streamlining the entire imaging workflow to ease the burden on providers and enable a more seamless experience for care teams and patients.
Book a demo
Transforming population health with AI-powered diagnostic screening programs
Explore our visionCould healthcare begin before illness ever shows up? Rather than waiting for patients to experience symptoms, what if care started with prevention, early detection, and access to critical diagnostic tools?
Finding and treating diseases, like breast cancer, at earlier stages increases survival rates.1 Screening healthy people helps make early detection more possible. By expanding screening for a range of diseases, more people have the chance to stay healthy longer—and this shift has the potential to significantly transform population health.
Population Health Suite of Solutions
Orchestrate and scale high-volume cancer screening and disease assessment programs
Find out moreLearn more
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
LOS ANGELES, November 5, 2025 — RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a US leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced it has acquired the assets of Alpha RT, a pioneer in remote MRI scanning solutions and services.
1) American Cancer Society. Breast Cancer Screening Guidelines, December 2023. Available on the https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. (Accessed July 16, 2025)
2) DeepHealth and Gleamer have a combined installed base of 2,700+ customer contracts across more than 50 countries, a comprehensive portfolio including 26 FDA-cleared and 22 CE-marked devices supporting 75+ indications, and a global footprint with 550+ employees across four continents. DeepHealth with Gleamer together anticipate achieving ARR approaching or exceeding $140 million by the end of 2026. We believe that these metrics make DeepHealth the leader in providing clinical radiology AI solutions worldwide.
Disclaimers: ProFound Detection V4 is FDA Cleared. ProFound AI V3 and PowerLook Density Assessment are FDA Cleared, CE Marked, and Health Canada Licensed. ProFound AI Risk is CE Marked and Health Canada Licensed, is not FDA Cleared, and is only available in the US for investigational use. Products may not be available in all geographies.